Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research | News
Search Refinements

Contract Research News

View news from other Pharmaceutical sectors:
121-135 of 2101 results
XBiotech starts research to develop antibody against Clostridium difficile
By PBR Staff Writer
XBiotech has launched a research and development (R&D) program to develop an oral monoclonal antibody against Clostridium difficile (C. difficile) infection.
Contract Research & Services > Contract Research > News
Ipsen and EpiVax partner to create next generation botulinum neurotoxin
By PBR Staff Writer
French pharmaceutical firm Ipsen and US biotechnology company EpiVax have completed a collaborative project that offers a novel approach to create next generation botulinum neurotoxin (BoNT) and targeted secretion inhibitor (TSI) therapeutics.
Contract Research & Services > Contract Research > News
US National Cancer Institute awards grant to Apogee for YELIVA prostate cancer research
The US National Cancer Institute (NCI) has awarded Apogee Biotechnology a $225,000 Small Business Innovation Research Program (SBIR) grant to support a pre-clinical study with YELIVA (ABC294640) for the treatment of prostate cancer.
Contract Research & Services > Contract Research > News
AstraZeneca and Eli Lilly expand immuno-oncology partnership to treat solid tumours
By PBR Staff Writer
AstraZeneca and Eli Lilly and Company have expanded their collaboration in cancer immunotherapy to test new drug combinations for treating solid tumours.
Contract Research & Services > Contract Research > News
Atara signs license and research deals with Australia's QIMR Berghofer Institute
By PBR Staff Writer
Atara Biotherapeutics has signed exclusive license and research agreements with Brisbane-based QIMR Berghofer Medical Research Institute to develop and commercialize allogeneic (off-the-shelf) cytotoxic T-lymphocytes (CTLs) directed against multiple epitopes of the Epstein-Barr virus and cytomegalovirus.
Contract Research & Services > Contract Research > News
Science 37 secures funding to accelerate clinical trial research
Science 37, a technology-enabled clinical research company, completed a $6.5m Series A financing co-led by Lux Capital and dRx Capital.
Contract Research & Services > Contract Research > News
Exact Imaging, Riverside Research partner to develop advanced tissue characterization techniques for prostate cancer
Exact Imaging has formed a partnership with Riverside Research, a not-for-profit, scientific-research company.
Contract Research & Services > Contract Research > News
Merck partners with UNESCO to build research capacity in Africa
Merck has launched in partnership with United Nations Educational, Scientific and Cultural Organization (UNESCO) the first edition of the UNESCO-Merck Africa Research Summit, to be held in Geneva, Switzerland.
Contract Research & Services > Contract Research > News
Crown Bioscience expands cardiovascular and metabolic disease capabilities
Crown Bioscience has entered a preclinical services alliance using the world’s largest collection of naturally occurring diabetic translational models.
Contract Research & Services > Contract Research > News
Lilly, ImaginAb enter into preclinical immuno-oncology research deal
By PBR Staff Writer
Eli Lilly and Company has entered into a preclinical research collaboration with ImaginAb to study potential new T-cell-based immuno-oncology therapies.
Contract Research & Services > Contract Research > News
UK’s NICE launches Office for Market Access for faster development of drugs
By PBR Staff Writer
The UK's National Institute for Health and Care Excellence (NICE) has launched its Office for Market Access (OMA) to speed up approvals of drugs and and health technologies in the country.
Contract Research & Services > Contract Research > News
GTx enrolls first patient in Phase II enobosarm trial to treat triple negative breast cancer
By PBR Staff Writer
GTx, a US-based biopharmaceutical company, has enrolled first patient in its Phase II clinical trial of enobosarm (GTx-024) to treat women with advanced, androgen receptor positive (AR+), triple negative breast cancer (TNBC).
Contract Research & Services > Contract Research > News
Vernalis buys US rights of Moxatag from Pragma Pharmaceuticals
By PBR Staff Writer
Vernalis has acquired the US rights of Moxatag amoxicillin extended-release tablets from Pragma Pharmaceuticals.
Contract Research & Services > Contract Research > News
UbiVac forms collaboration with Johnson & Johnson Innovation
UbiVac, a privately held clinical stage Immuno-Oncology company, has formed a collaboration with Janssen Biotech (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Contract Research & Services > Contract Research > News
Mesoblast's MPC therapy trial reports better cardioprotective effect
By PBR Staff Writer
The Phase 2 trial results of Mesoblast's mesenchymal precursor cell (MPC) therapy claimed to have greatercardioprotective effect in the subset of patients with more advanced heart failure.
Contract Research & Services > Contract Research > News
121-135 of 2101 results